Treatment of Elderly Patients with Overactive Bladder: Has Mirabegron Come of Age?

Publication date: Available online 17 November 2019Source: European UrologyAuthor(s): Tom Marcelissen, Kevin Rademakers
Source: European Urology - Category: Urology & Nephrology Source Type: research

Related Links:

ConclusionsAltogether, these findings establish that urinary metabolites of mitochondrial dysfunction, ketosis and oxidative stress can be potential biomarkers of OAB severity and diagnosis.
Source: International Urogynecology Journal - Category: OBGYN Source Type: research
ConclusionsWe found no changes in MOCA scores between OAB medication and control groups after controlling for age, depression, and polypharmacy after 12  months of follow-up.
Source: International Urogynecology Journal - Category: OBGYN Source Type: research
Overactive bladder is a common and bothersome condition which has a major and measurable impact on sufferers' quality of life. The cardinal symptom of urgency, with or without urgency incontinence, frequency and nocturia is thought to be caused by abnormalities in detrusor smooth muscle function and/or sensory pathways. A structured assessment approach is of importance, including a detailed history of symptoms, medical and drug history and lifestyle factors such as fluid intake. Conservative management revolves around the key principles of fluid modification, avoidance of potential triggers and bladder retraining.
Source: Obstetrics, Gynaecology and Reproductive Medicine - Category: OBGYN Authors: Tags: Review Source Type: research
This study is the first paper to test simultaneously the effects of 10 anticholinergic drugs used currently for the therapy of OAB, on the P-glycoprotein. PMID: 31787715 [PubMed - in process]
Source: Biological and Pharmaceutical Bulletin - Category: Drugs & Pharmacology Authors: Tags: Biol Pharm Bull Source Type: research
Condition:   Overactive Bladder Interventions:   Drug: Botulinum toxin type A injection;   Drug: Botulinum Toxin Type A Injection [Botox] Sponsor:   Hugel Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Overactive Bladder Interventions:   Drug: Botulinum toxin type A injection;   Drug: Botulinum Toxin Type A Injection [Botox] Sponsor:   Hugel Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Overactive Bladder Interventions:   Drug: Botulinum toxin type A injection;   Drug: Botulinum Toxin Type A Injection [Botox] Sponsor:   Hugel Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
ConclusionThe polymorphisms of the ADRB3, ROCK2, and GEF genes were present in both OAB group and healthy controls, but were not associated with OAB syndrome.
Source: World Journal of Urology - Category: Urology & Nephrology Source Type: research
AbstractPurpose of ReviewTo provide an overview of the appropriate evaluation of elderly men with urinary incontinence and an updated review of treatment options available to these patients.Recent FindingsAdding pelvic floor physical therapy to bladder training exercises is more effective for treating overactive bladder than bladder training alone. Beta-3 adrenergic agonists are a safe and effective alternative to anticholinergic therapy in older adults. Sacral neuromodulation is safe and effective in older adults and may benefit men with incomplete bladder emptying. A de-obstructing surgery may benefit men with both under...
Source: Current Geriatrics Reports - Category: Geriatrics Source Type: research
To determine whether the presence of detrusor overactivity (DO) is associated with the 12-week and 12-month clinical outcomes of selective bladder denervation (SBD) in women with refractory overactive bladder (OAB).
Source: Urology - Category: Urology & Nephrology Authors: Source Type: research
More News: Overactive Bladder | Overactive Bladder Syndrome | Urology & Nephrology